PHERECYDES PHARMA overview

Regulatory News: PHERECYDES Pharma (FR0011651694 – ALPHE), a biotechnology company specializing in extended phage therapy for treating antibiotic-resistant and/or complicated bacterial infections (the "Company"), announced today that the shareholders of Pherecydes Pharma (Pherecydes) and Erytech Pharma (Erytech) have approved the merger of the two companies on the basis of an exchange ratio of 4 Pherecydes shares for 15 Erytech shares (the "Merger"). At the Erytech Combined Shareholders'...

Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced today that the Lyon Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Erytech Pharma (Erytech). Pherecydes Pharma, which voluntarily intervened in the legal proceedings initiated by Akkadian (Pherecydes Pharma’s Press release of June 5, 2023), is pleased with...

Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has submitted an application for the approval of a phase I clinical study in infective endocarditis caused by Staphylococcus aureus (S. aureus) with the ANSM (the French National Agency for the Safety of Medicines). Endocarditis is an infection of the endocardium (inner layer of the heart)...

Regulatory News: Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in extended phage therapy for treating antibiotic-resistant and/or complicated bacterial infections, announces that it has been informed that Akkadian Partners has initiated legal proceedings against Erytech to obtain the postponement of the vote at the Annual General Meeting on June 23 on the merger with Pherecydes. For further information, please refer to the press release issued...

Regulatory News: PHERECYDES Pharma (FR0011651694 – ALPHE), a biotechnology company specializing in extended phage therapy for treating antibiotic-resistant and/or complicated bacterial infections, announces that it has published the exemption document relating to the proposed combination with Erytech Pharma (ISIN code: FR0011471135, ticker: ERYP). The document may be consulted on the company's website at www.pherecydes-finance.com in the General Meeting section. *** About PHERECYDES Founded in...

Regulatory News: PHERECYDES Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in extended phage therapy for treating antibiotic-resistant and/or complicated bacterial infections (the "Company"), announces progress on the strategic combination with ERYTECH and its implementation toward the merger. Entry into a definitive merger agreement between PHERECYDES and ERYTECH In relation to the announced merger of PHERECYDES into ERYTECH (the “ Proposed Merger ”),...

Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections (the “ Company ”), presented part of its analytical performance plan adapted to its Phagogram 1.5 on April 15, 2023, at the 33 rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen (Denmark). The phagogram is an in vitro diagnostic test designed to check the...

Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections (the “ Company ”), today announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps, has initiated coverage of its shares. In its initiation study published on April 6, 2023, TP ICAP Midcap began covering the stock with a “Buy” recommendation and...